Press Releases

NEW YORK, Dec. 16, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight lethal disease-causing pathogens, announced today that the Delaware Chancery Court has denied its motion for reconsideration of certain aspects of the Court's post-trial decision in the litig...

NEW YORK, Nov. 3, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight lethal disease causing pathogens, announced today that management will host a conference call and simultaneous webcast to provide a quarterly business update at 4:30 P.M. ET on Thursday, Novem...

NEW YORK, Aug. 24, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, announced today that it has been awarded a $7.7 million grant from the National Institutes of Health (NIH) to develop an antiviral drug for treating and preventing Lass...

NEW YORK, July 26, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight lethal disease causing pathogens, announced today that its Chief Executive Officer, Dr. Eric Rose, and Executive Vice President, Daniel Luckshire, will participate in the upcoming Goldman Sac...

NEW YORK, June 27, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA) announced today that the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (BARDA) has advised that the protest filed against the contract it awarded to SIGA for the sale of SIGA's smallpox antiviral ST...

NEW YORK, May 13, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human ...

NEW YORK, April 29, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it will report first quarter 2011 results on Thursday, May 5, 2011. Management will host a conference call and simultaneous webcast to disc...

NEW YORK, March 9, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today reported its financial results for the fourth quarter and year ended December 31, 2010. Revenue for the year ended 2010 was $19.2 million compared to $13.8...

NEW YORK, Feb. 21, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today that the Biomedical Advanced Research and Development Authority (BARDA), a unit of the U.S. Department of Health and Human Services, has advised that i...

NEW YORK, Feb. 11, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today that it had appointed Daniel J. Luckshire as its new Executive Vice President and Chief Financial Officer, effective as of February 10, 2011. D...